One of the most typical and widespread variants of the toxic effect of drugs on the body in general and on the liver in particular is the use of anticancer drugs. However, there is currently no standard treatment strategy for such lesions. Aim: to investigate the effectiveness and safety of using of the Livodinol^® complex in drug-induced hepatitis induced by cytostatic therapy for breast cancer. Object and research methods. 38 patients who received 4–6 courses of polychemotherapy after radical surgical interventions for breast cancer were examined. Patients of the 1st group (n=19) received standard detoxification therapy, patients of the 2nd group (n=19) additionally received the drug levodinol for 1 month. Results. The use of Livodinol^® made it possible to significantly reduce the severity of subjective manifestations (pain, dyspeptic and asthenic syndromes) and clinical symptoms (increased liver size, scleral and skin icterus) of drug-induced hepatitis, as well as to significantly accelerate the normalization of biochemical indicators of liver function. The use of Livodinol^® was not accompanied by side effects in any of the patients. No toxic or allergic manifestations were noted. Conclusion. The data obtained allow us to recommend the use of Livodinol^® for 1 month in the case of drug-induced hepatitis, in particular, induced by the use of anticancer therapy.